Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Investigational New Drugs
|
August 31, 2002
A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation
Rhona McMenemin, Graham Macdonald, Leslie Moffat, et al.
Case Reports in Oncology
|
August 27, 2010
Isolated Meningeal Recurrence of Transitional Cell Carcinoma of the Bladder
Catherine Butchart, Asa Dahle-Smith, Donald Bissett, et al.
Pharmacoeconomics
|
January 19, 2013
Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal
Mary Kilonzo, Jenni Hislop, Andrew Elders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2004
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors
Ramon Salazar, Donald Bissett, Chris Twelves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2006
Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer
Russell D Petty, Keith M Kerr, Graeme I Murray, et al.
Experimental Dermatology
|
June 11, 2005
Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible
Amanda Greatens, Tomohiro Hakozaki, Amy Koshoffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
Alan V Boddy, E Ruth Plummer, Radha Todd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2005
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer
Donald Bissett, Ken J O'Byrne, J von Pawel, et al.
International Journal of Oncology
|
May 9, 2009
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
Leonard W Seymour, David R Ferry, David J Kerr, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Investigational New Drugs
|
August 31, 2002
A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation
Rhona McMenemin, Graham Macdonald, Leslie Moffat, et al.
Case Reports in Oncology
|
August 27, 2010
Isolated Meningeal Recurrence of Transitional Cell Carcinoma of the Bladder
Catherine Butchart, Asa Dahle-Smith, Donald Bissett, et al.
Pharmacoeconomics
|
January 19, 2013
Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal
Mary Kilonzo, Jenni Hislop, Andrew Elders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2004
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors
Ramon Salazar, Donald Bissett, Chris Twelves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2006
Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer
Russell D Petty, Keith M Kerr, Graeme I Murray, et al.
Experimental Dermatology
|
June 11, 2005
Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible
Amanda Greatens, Tomohiro Hakozaki, Amy Koshoffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
Alan V Boddy, E Ruth Plummer, Radha Todd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2005
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer
Donald Bissett, Ken J O'Byrne, J von Pawel, et al.
International Journal of Oncology
|
May 9, 2009
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
Leonard W Seymour, David R Ferry, David J Kerr, et al.
Page
of 1